Sun Pharmaceutical Industries (NSE:SUNPHARMA, BOM:524715) posted a decline in its consolidated net profit to 21.5 billion Indian rupees in the fiscal fourth quarter ended March 31, against 26.5 billion rupees a year ago.
Earnings per share contracted to 9.0 rupees compared with the year-ago figure of 11.1 rupees, according to a Thursday filing to the Indian stock exchanges by the pharmaceutical company.
Revenue from operations in fiscal Q4, however, increased to 129.6 billion rupees from 119.8 billion rupees a year earlier.
The company's board declared a final dividend of 5.50 rupees per equity share of 1 rupee each.
Sun Pharma's shares were down nearly 3% in recent trade.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。